Kurve Therapeutics
Kurve Therapeutics is a Lynnwood, Washington-based clinical-stage medtech company developing the patented ViaNase device and Controlled Particle Dispersion (CPD) technology for non-invasive, intranasal nose-to-brain drug delivery to treat neurodegenerative diseases such as Alzheimer's, Parkinson's, and glioblastoma.
- Company typePrivate
- Founded2001
- HeadquartersLynnwood, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kurve Therapeutics does
Kurve Therapeutics, Inc. (formerly Kurve Technology, Inc.) is a Lynnwood, Washington-based clinical-stage medtech company founded in 2001 that develops non-invasive, intranasal drug delivery systems targeting central nervous system disorders. Its core platform is Controlled Particle Dispersion (CPD), a patented technology that generates a focused, turbulent aerosol flow to navigate the nasal cavity and access the olfactory mucosa, bypassing the blood-brain barrier to deliver medication directly to the brain. The hardware manifestation is the ViaNase Intelligent Delivery Device — a battery-powered, pocket-sized, one-button atomizer — paired with proprietary drug formulations including an intranasal insulin candidate for Alzheimer's disease and mild cognitive impairment. Internal and clinical data report up to 30x more brain delivery than IV infusion, with one head-to-head study reporting 3,000% greater delivery; the platform is supported by 18 peer-reviewed publications and five double-blind, placebo-controlled Phase II studies, with Phase III readiness in three disease states.
The business model combines a B2B technology-licensing and drug-formulation-collaboration model (targeting CNS researchers at academic institutions such as Johns Hopkins, Harvard, Karolinska, and Wake Forest, as well as pharmaceutical companies developing monoclonal antibodies and larger peptides) with proprietary drug commercialization upon regulatory approval. The company is raising up to $50 million through a Regulation A+ equity crowdfunding offering via Rialto Markets to fund Phase III trials. Named partners include Orgenesis for glioblastoma and Hospital Infantil Universitario Niño Jesús (Madrid) for cell-based therapy manufacturing, with international clinical presence in the U.S., Sweden, and the Netherlands. Leadership is a four-person executive team led by founder/CEO Marc Giroux, the lead or sole inventor on Kurve's IP.
Revenue is not disclosed and Kurve operates as pre-revenue; income is expected to derive from future licensing royalties, one-time technology licenses, and proprietary drug sales rather than current operations. Marketing is conducted primarily through the corporate website, peer-reviewed publications, industry conferences (e.g., LSI USA '23), press releases, a dedicated Nasal Drug Delivery blog, and a multi-platform social media presence.
Kurve Therapeutics firmographics
Firmographics- Name
- Kurve Therapeutics
- Legal name
- Kurve Therapeutics, Inc.
- Website
- https://kurvetx.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kurve Therapeutics is a Lynnwood, Washington-based clinical-stage medtech company developing the patented ViaNase device and Controlled Particle Dispersion (CPD) technology for non-invasive, intranasal nose-to-brain drug delivery to treat neurodegenerative diseases such as Alzheimer's, Parkinson's, and glioblastoma.
- Ownership category
- akta.pro rank
Kurve Therapeutics industry classification
Industry- Product category
- Intranasal Drug Delivery
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM)
Keywords
Where Kurve Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Lynnwood
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Kurve Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Technology Licensing: Kurve licenses its CPD technology and ViaNase device to pharmaceutical companies developing CNS drugs, enabling them to reformulate existing or new therapies for intranasal delivery to bypass the blood-brain barrier.
- Drug Formulation Services: The company develops proprietary drug formulations for neurodegenerative diseases and may commercialize these as branded therapies upon successful clinical trials and regulatory approval.
- Equity Crowdfunding: The company is raising capital through Regulation A+ equity crowdfunding, offering shares to public investors starting at $580 for 100 shares.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One time | Regulation A+ Investment Minimum |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Kurve Therapeutics product offering
Product offeringCore offering
Kurve Therapeutics develops and commercializes a patented Controlled Particle Dispersion (CPD) intranasal drug delivery technology delivered via the ViaNase Intelligent Delivery device, enabling non-invasive nose-to-brain delivery that bypasses the blood-brain barrier. The company pairs the CPD platform with proprietary drug formulations (including intranasal insulin) for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and related CNS disorders.
Product overview
Kurve Therapeutics offers a next-generation medtech platform centered on the ViaNase Intelligent Delivery device, which incorporates the patented Controlled Particle Dispersion (CPD) technology. This hardware-software combination enables non-invasive nasal drug delivery directly to the brain, bypassing the blood-brain barrier. The company pairs its delivery technology with proprietary drug formulations including intranasal insulin for neurodegenerative diseases. The CPD technology serves as the core platform enabling delivery of various pharmaceutical formulations, while the ViaNase device is the hardware interface for patient administration. Kurve has developed multiple formulations including intranasal insulin, with ongoing development for additional therapeutic agents for conditions including Alzheimer's, Parkinson's, and glioblastoma.
Differentiator
Problem solved
Functional benefit
Brands
- ViaNase™ Intelligent Delivery: The company's core drug delivery device using Controlled Particle Dispersion (CPD) technology for intranasal drug delivery to bypass the blood-brain barrier
Products and services
- ViaNase Intelligent Delivery Device A nasal drug delivery device that uses Controlled Particle Dispersion (CPD) technology to deliver medication directly to the brain via the olfactory mucosa, bypassing the blood-brain barrier. Designed for pharmaceutical partners, academic researchers, and clinical trial use.
- Kurve Intranasal Insulin Product An insulin formulation designed for intranasal delivery via the ViaNase device for treatment of Alzheimer's disease, mild cognitive impairment, and other neurodegenerative conditions.
Quantifiable outcome
- 30x more medication delivered to brain than IV infusions
- +4 more outcomes
Companies that use Kurve Therapeutics
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles3 records
Kurve Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Kurve Therapeutics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- OrgenesiscoreCollaboration between Kurve and Orgenesis for preclinical study on cell-based oncolytic virus bearing product for glioblastoma treatment. Orgenesis provides mesenchymal stem-cell-based product while Kurve provides its patented CPD intranasal drug delivery technology to bypass the blood-brain barrier. The study demonstrated over 50% tumor reduction in a murine glioblastoma model.
- Hospital Infantil Universitario Niño JesúscoreInvolved in the Orgenesis collaboration, Hospital Niño Jesús in Madrid performs clinical-grade manufacturing using Orgenesis Mobile Processing Units and Lab (OMPUL) for the cell-based product intended for intravenous administration, with plans for future intranasal delivery using Kurve's technology.
- Harvard Medical SchoolcoreRecent and ongoing collaboration with Harvard for clinical research on cognition in diabetics using Kurve's intranasal drug delivery technology.
- Johns HopkinscoreOngoing collaboration with Johns Hopkins for multiple clinical trials including Alzheimer's Disease research, Multiple Sclerosis cognition studies, Neuropathic Pain research, and selective CNS uptake studies. Kurve's technology featured in peer-reviewed publications.
- Karolinska InstitutecoreRecent and ongoing collaboration with Karolinska Institute in Sweden for mood and anxiety disorders clinical research using Kurve's intranasal drug delivery technology.
Scale indicators10 records
Recent moves8 records
Expansion highlights6 records
Kurve Therapeutics competitors and assessment
Company assessmentEmerging players
- AeroFact: AeroFact is developing intranasal insulin for Alzheimer's disease using a similar delivery approach to Kurve's ViaNase. It is an emerging player directly overlapping in the intranasal insulin for CNS disease niche.
Direct peers
- OptiNose: OptiNose develops intranasal drug delivery devices targeting CNS and respiratory conditions using proprietary breath-powered technology. It is a direct competitor in the nasal-to-brain / targeted nasal delivery space with FDA-approved products, making it the closest commercial-stage comparable to Kurve's ViaNase platform.
- Impel Pharmaceuticals: Impel (now part of AbbVie/formerly) developed the POD technology for intranasal drug delivery targeting the upper nasal cavity, with a CNS focus including acute migraine (Trudhesa). It is a direct peer in nose-to-brain delivery and CNS therapeutics commercialization.
Broad incumbents
- Aptar Pharma: Aptar Pharma is a global leader in nasal drug delivery devices and dispensing systems, supplying a broad portfolio of nasal spray pumps and devices to pharma partners. As a broad incumbent, it competes for the same licensing/partnership opportunities Kurve targets, though with a much wider device portfolio.
- Nemera: Nemera is a drug delivery device manufacturer with a significant intranasal delivery portfolio including electronic and preservative-free systems. As a broad incumbent, it competes with Kurve in nasal device partnerships for CNS and respiratory indications.
- Becton Dickinson (BD): BD Pharmaceutical Systems is a major supplier of drug delivery devices including prefilled syringes, autoinjectors, and nasal systems. As a broad incumbent, BD represents the type of strategic acquirer or large partner that Kurve would likely need for commercialization.
- Biogen: Biogen is a major CNS-focused biopharmaceutical company with established Alzheimer's, MS, and ALS programs. It represents both a potential strategic acquirer/partner for Kurve and the type of established incumbent whose delivery modalities Kurve's platform would compete with.
- West Pharmaceutical Services: West Pharmaceutical Services provides drug delivery device components and injectable/inhalation delivery systems to pharma and biotech. As a broad incumbent in drug delivery, it is comparable to Kurve's platform business in serving pharma formulation and delivery needs.
Regional players
- Cassava Sciences: Cassava Sciences (US) develops treatments for Alzheimer's disease and CNS disorders. While it uses oral rather than intranasal delivery, it is a relevant comparable in late-stage CNS drug development, market size, and the binary trial readout dynamics Kurve faces.
- BioDelivery Sciences International: BDSI developed and commercialized specialty pharmaceutical products using novel delivery technologies, particularly in pain and CNS. It is comparable to Kurve in combining proprietary delivery technology with branded drug formulations, and demonstrates the typical small-cap commercial trajectory.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Kurve Therapeutics social profiles
Digital presenceKurve Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kurve Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Kurve Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kurve Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kurve Therapeutics
What does Kurve Therapeutics do?
Kurve Therapeutics develops and commercializes a patented Controlled Particle Dispersion (CPD) intranasal drug delivery technology delivered via the ViaNase Intelligent Delivery device, enabling non-invasive nose-to-brain delivery that bypasses the blood-brain barrier. The company pairs the CPD platform with proprietary drug formulations (including intranasal insulin) for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and related CNS disorders.
Is Kurve Therapeutics a public or private company?
Kurve Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Kurve Therapeutics founded?
Kurve Therapeutics was founded in 2001. It employs 11 to 50 people.
Where is Kurve Therapeutics based?
Kurve Therapeutics is headquartered in Lynnwood, United States, in the North America region.
How does Kurve Therapeutics make money?
Three revenue lines are on record. Technology Licensing is the primary driver. The others are drug Formulation Services and equity Crowdfunding.
Who are Kurve Therapeutics's main competitors?
AeroFact is listed as an emerging player. Direct peers are OptiNose and Impel Pharmaceuticals. Broad incumbents are Aptar Pharma, Nemera, Becton Dickinson (BD), Biogen and West Pharmaceutical Services. Regional players are Cassava Sciences and BioDelivery Sciences International.
Does Kurve Therapeutics have an API?
No public API is recorded for Kurve Therapeutics.
What industry is Kurve Therapeutics in?
Kurve Therapeutics's product category is Intranasal Drug Delivery. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 339112 and its SIC code is 3841.